	US 12,252,515 B2
	Compositions and methods for inhibiting Wnt signaling
Min Dong, Weatogue, CT (US); Liang Tao, Boston, MA (US); Rongsheng Jin, Irvine, CA (US); Peng Chen, Oakland, CA (US); and Aina He, Boston, MA (US)
Assigned to Children's Medical Center Corporation, Boston, MA (US); and The Regents of the University of California, Oakland, CA (US)
Appl. No. 16/962,338
Filed by Children's Medical Center Corporation, Boston, MA (US); and The Regents of the University of California, Oakland, CA (US)
PCT Filed Jan. 14, 2019, PCT No. PCT/US2019/013440 § 371(c)(1), (2) Date Jul. 15, 2020, PCT Pub. No. WO2019/143552, PCT Pub. Date Jul. 25, 2019.
Claims priority of provisional application 62/670,225, filed on May 11, 2018.
Claims priority of provisional application 62/618,042, filed on Jan. 16, 2018.
Prior Publication US 2020/0339636 A1, Oct. 29, 2020
Int. Cl. C07K 14/33 (2006.01); A61K 38/00 (2006.01); A61P 35/00 (2006.01)

CPC C07K 14/33 (2013.01) [A61P 35/00 (2018.01); A61K 38/00 (2013.01); C07K 2319/21 (2013.01); C07K 2319/30 (2013.01)]

9 Claims

1. A method of reducing Wnt signaling, the method comprising administering to a subject in need thereof, a therapeutically effective amount of an isolated polypeptide comprising a TcdB fragment consisting of the amino acid sequence of SEQ ID NO: 2, wherein the isolated polypeptide does not comprise an amino acid sequence that is 100% identical to amino acids 1114-1835 of SEQ ID NO: 1.